Nexpovio (Selinexor)

Nexpovio acts on malignant cells by blocking nuclear export pathways, providing therapeutic options for hematologic cancers.

• Relapsed or refractory multiple myeloma: provides an additional option for patients who have progressed after standard therapies.
• Relapsed or refractory diffuse large B‑cell lymphoma: offers a treatment alternative for patients whose disease is refractory to conventional regimens.
• Investigational solid‑tumor indications: currently evaluated in clinical studies for potential benefit in various solid cancers.

• Selinexor binds to exportin 1 (XPO1), the key nuclear export protein, preventing the transport of tumor suppressor proteins and oncogenic mRNA from the nucleus to the cytoplasm. This results in nuclear retention and activation of tumor suppressor pathways while inhibiting the expression of oncogenic drivers, leading to cancer cell apoptosis and growth arrest.

Selinexor may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness affecting daily activities.
• Nausea: feeling of sickness often accompanied by vomiting.
• Anorexia: reduced appetite leading to weight loss.
• Thrombocytopenia: lowered platelet count increasing bleeding risk.
• Anemia: decreased red blood cells causing weakness.
• Vomiting: expulsion of stomach contents.

Serious or Rare Side Effects

• Severe neutropenia: markedly low neutrophil count raising infection risk.
• Hepatic toxicity: elevated liver enzymes or liver injury.
• Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.
• Pulmonary embolism: blood clot in the lungs presenting with sudden shortness of breath.
• Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.

Before initiating selinexor therapy, clinicians should assess baseline health status and monitor for potential complications.

• Monitor blood counts: regular CBC to detect cytopenias.
• Assess liver function: periodic LFTs to identify hepatic toxicity.
• Avoid in uncontrolled infections: defer treatment until infection is resolved.
• Use effective contraception: teratogenic risk unknown, so pregnancy must be avoided.
• Review concomitant CYP3A4 inhibitors: may increase drug exposure.
• Store at below 25°C: keep in the original pack, protect from moisture.

Selinexor can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors: may raise selinexor plasma levels and increase toxicity.
• QT‑prolonging agents: additive risk of cardiac arrhythmias.
• Anticoagulants: heightened bleeding risk due to thrombocytopenia.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers: may lower selinexor effectiveness.
• Antacids containing aluminum or magnesium: can reduce oral absorption.
• Concurrent myelosuppressive chemotherapy: may exacerbate cytopenias.